Stela Gheorghita1, Ludmila Birca2, Ala Donos3, Annemarie Wasley4, Ion Birca1, Radu Cojocaru1, Anatol Melnick1, Silviu Ciobanu5, Liudmila Mosina4, Margaret M Cortese6, Umesh D Parashar6, Ben Lopman6. 1. National Center for Public Health. 2. Chisinau City Infectious Diseases Hospital for Children. 3. Chisinau Municipal Hospital for Children, Republic of Moldova. 4. Vaccine-Preventable Diseases and Immunization, World Health Organization Regional Office for Europe, Copenhagen, Denmark. 5. World Health Organization Regional Office for Moldova, Chisinau. 6. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND: The Republic of Moldova was the first low- to middle-income country in the World Health Organization European Region to introduce rotavirus vaccine (July 2012). We aimed to assess the impact of the rotavirus vaccine program and estimate vaccine effectiveness (VE). METHODS: Surveillance for rotavirus gastroenteritis was conducted in 2 hospitals in the capital city of Chisinau starting in September 2009. Monthly rotavirus admissions by age were examined before and after introduction of rotavirus vaccination using interrupted time-series analyses. We performed a case-control study of VE by comparing rotavirus case patients with test-negative controls. RESULTS: Coverage with at least 1 dose of vaccine increased from 35% in year 1 to 55% in year 2 for children <1 year of age. The percentage of hospital admissions positive for rotavirus fell from 45% in the prevaccine period to 25% (rate reduction, 36%; 95% confidence interval [CI], 26%-44%) and 14% (rate reduction, 67%; 95% CI, 48%-88%) in the first and second years after vaccine introduction, respectively, among children aged <5 years. Reductions were most pronounced among those aged <1 year. Significant reductions among cohorts too old to be vaccinated suggest indirect benefits. Two-dose VE was 79% (95% CI, 62%-88%) against rotavirus hospitalization and 84% (95% CI, 64%-93%) against moderate to severe rotavirus. CONCLUSIONS: These results consistently point to profound direct and herd immunity impacts of the rotavirus vaccine program in young children in the Republic of Moldova. Vaccine coverage was modest in these early years following introduction, so there remains potential for further disease reductions. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: The Republic of Moldova was the first low- to middle-income country in the World Health Organization European Region to introduce rotavirus vaccine (July 2012). We aimed to assess the impact of the rotavirus vaccine program and estimate vaccine effectiveness (VE). METHODS: Surveillance for rotavirus gastroenteritis was conducted in 2 hospitals in the capital city of Chisinau starting in September 2009. Monthly rotavirus admissions by age were examined before and after introduction of rotavirus vaccination using interrupted time-series analyses. We performed a case-control study of VE by comparing rotavirus case patients with test-negative controls. RESULTS: Coverage with at least 1 dose of vaccine increased from 35% in year 1 to 55% in year 2 for children <1 year of age. The percentage of hospital admissions positive for rotavirus fell from 45% in the prevaccine period to 25% (rate reduction, 36%; 95% confidence interval [CI], 26%-44%) and 14% (rate reduction, 67%; 95% CI, 48%-88%) in the first and second years after vaccine introduction, respectively, among children aged <5 years. Reductions were most pronounced among those aged <1 year. Significant reductions among cohorts too old to be vaccinated suggest indirect benefits. Two-dose VE was 79% (95% CI, 62%-88%) against rotavirus hospitalization and 84% (95% CI, 64%-93%) against moderate to severe rotavirus. CONCLUSIONS: These results consistently point to profound direct and herd immunity impacts of the rotavirus vaccine program in young children in the Republic of Moldova. Vaccine coverage was modest in these early years following introduction, so there remains potential for further disease reductions. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Jim P Buttery; Stephen B Lambert; Keith Grimwood; Michael D Nissen; Emma J Field; Kristine K Macartney; Jonathan D Akikusa; Julian J Kelly; Carl D Kirkwood Journal: Pediatr Infect Dis J Date: 2011-01 Impact factor: 2.129
Authors: Catherine Yen; Jacqueline E Tate; Terri B Hyde; Margaret M Cortese; Benjamin A Lopman; Baoming Jiang; Roger I Glass; Umesh D Parashar Journal: Hum Vaccin Immunother Date: 2014-04-22 Impact factor: 3.452
Authors: Maria Y T Ichihara; Laura C Rodrigues; Carlos A S Teles Santos; Maria da Gloria L C Teixeira; Sandra R De Jesus; Sheila M Alvim De Matos; Jose P Gagliardi Leite; Mauricio L Barreto Journal: Vaccine Date: 2014-02-05 Impact factor: 3.641
Authors: Maria Cleonice A Justino; Alexandre C Linhares; Tatiana M Lanzieri; Yllen Miranda; Joana D'arc P Mascarenhas; Erika Abreu; Sylvia F S Guerra; Alessilva S L Oliveira; Veronilce B da Silva; Nervo Sanchez; Nadia Meyer; Fakrudeen Shafi; Eduardo Ortega-Barria; Montse Soriano-Gabarró; Romulo E Colindres Journal: Pediatr Infect Dis J Date: 2011-05 Impact factor: 2.129
Authors: Karol Cotes-Cantillo; Angel Paternina-Caicedo; Wilfrido Coronell-Rodríguez; Nelson Alvis-Guzmán; Umesh D Parashar; Manish Patel; Fernando De la Hoz-Restrepo Journal: Vaccine Date: 2014-03-31 Impact factor: 3.641
Authors: Manish M Patel; Maritza Patzi; Desiree Pastor; Aleida Nina; Yelin Roca; Leovigildo Alvarez; Volga Iniguez; Rosario Rivera; Ka Ian Tam; Osbourne Quaye; Michael Bowen; Umesh Parashar; Lucia Helena De Oliveira Journal: BMJ Date: 2013-06-19
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Liudmyla I Chernyshova; Nataliya M Radionova; Iryna V Demchyshyna; Liudmyla S Kotlik; Oleksandra B Sadkova; Elena O Samoilovich; Galina V Semeiko; Danni S Daniels; Adam L Cohen; Negar Aliabadi Journal: Vaccine Date: 2017-12-01 Impact factor: 4.169